Publications Office of the EU
D-Stuttgart: Pharmaceutical products - EU tenders
DisplayCustomHeader
Procurement Detail Actions Portlet
OP Portal - Procurement - Details

This page contains content generated automatically to improve findability and accessibility

- indicates text translated automatically in your browsing language

D-Stuttgart: Pharmaceutical products

  • Awarded
    17/05/2013
  • Today
    26/08/2026
Status
Awarded
Type of contract
Supplies
Subject for Renewal
No
Buyer
Not available
Place of performance
NUTS code: DE1 Baden-Württemberg
Location of buyer
NUTS code: Not available
Business sector (Main CPV)
33600000 Pharmaceutical products
Total estimated contract value (excluding VAT)
Not available
Total final contract value (excluding VAT)
Not available
Tender reference number
Not available
Description

The subject of this contract is the grant by the pharmaceutical company of discounts pursuant to Paragraph 130a(8) of the SGB V for all medicinal products containing the active ingredients infliximab and golimumab.

Submission Method
Not available
Tenders may be submitted
Not applicable
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
The procurement involves the establishment of a framework agreement
Conditions for opening tenders (date)
Not available
Place of performance
Award method
Lowest price
Estimated value
Not available
Final contracted value
Not available
Award of contract
Official name: MSD Sharp & Dohme GmbH
Postal address: Lindenplatz 1
Town: Haar
Postal code: 85540
Country: DEU
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.